Explore a 41-minute webinar presented by Dr. Sandhya Sharma from Baylor College of Medicine's Center for Cell and Gene Therapy on enriching antigen-specific T-cells for immunotherapy. Delve into the challenges of manufacturing virus-antigen-specific T-cells (VSTs) for treating virus-associated malignancies, focusing on the selective depletion of CD45RA expressing cells. Learn about Dr. Sharma's expertise in generating clinically potent T-cells specific to Epstein-Barr (EBV) antigens for EBV-positive lymphomas. Gain insights into overcoming obstacles in T-cell therapies, particularly when dealing with low-frequency VSTs in immunosuppressive tumor environments. Healthcare professionals can earn PACE credits by watching the webinar and following the provided instructions. Connect with Labroots on various social media platforms for more scientific content and updates.
Selective Depletion of CD45RA Expressing Cells to Enrich Antigen-Specific T-Cells for Immunotherapy
Overview
Syllabus
Selective Depletion of CD45RA Expressing Cells to Enrich Antigen Specific T-Cells for Immunotherapy
Taught by
Labroots
Related Courses
-
Understanding the Mechanisms of Resistance in CAR T Immunotherapy for Lymphoma and Strategies to Overcome Them
-
CAR-T Cells and Cancer Immunotherapy - Part 3
-
Monitoring of Circulating CAR T Cells
-
Identification of Tumor-Reactive T Cell Receptors Through Functional Single Cell Interaction Analysis for Personalized T Cell Therapy
-
CAR T at UCLA - Driving the Progress of Engineered Cell Therapy
-
CD3ζ as a Novel Integration Site for Reprogramming Immune Cells with Chimeric Antigen Receptors
